CD274 (PD-L1) - Comprehensive Cross-Database Identifier & Functional Mapping Reference
╔══════════════════════════════════════════════════════════════════════════════╗
║ CD274 / PD-L1 / B7-H1 ║
║ Programmed Cell Death 1 Ligand 1 ║
║ ║
║ A critical immune checkpoint ligand that binds PD-1 to inhibit ║
║ T cell activation. Major therapeutic target in cancer immunotherapy. ║
╚══════════════════════════════════════════════════════════════════════════════╝
Section 1: Gene Identifiers
| Attribute | Value |
|---|
| HGNC ID | HGNC:17635 |
| Approved Symbol | CD274 |
| Approved Name | CD274 molecule |
| Previous Symbols | PDCD1LG1 |
| Aliases | PD-L1, PDL1, B7-H1, B7H1, B7-H |
| Locus Type | Gene with protein product |
| Status | Approved |
| Database | Identifier |
|---|
| Ensembl Gene | ENSG00000120217 |
| NCBI Entrez Gene | 29126 |
| OMIM | 605402 |
Genomic Location
| Attribute | Value |
|---|
| Chromosome | 9 |
| Cytogenetic Band | 9p24.1 |
| Start Position | 5,450,503 (GRCh38) |
| End Position | 5,470,566 (GRCh38) |
| Strand | + (forward) |
| Genomic Accession | NC_000009.12 |
Gene Groups
- CD molecules
- Receptor ligands
- V-set domain containing
- C2-set domain containing
- B7 family
Section 2: Transcript Identifiers
Ensembl Transcripts
Total: 5 transcripts
| Transcript ID | Biotype | Start | End | UTR5 | UTR3 |
|---|
| ENST00000381577 | protein_coding | 5,450,542 | 5,470,554 | 5,456,100-5,456,113 | 5,467,863-5,470,554 |
| ENST00000381573 | protein_coding | 5,450,503 | 5,470,566 | 5,456,100-5,456,113 | 5,467,863-5,470,566 |
| ENST00000474218 | protein_coding_CDS_not_defined | 5,457,384 | 5,463,238 | - | - |
| ENST00000492923 | protein_coding_CDS_not_defined | 5,462,935 | 5,465,912 | - | - |
| ENST00000498261 | protein_coding_CDS_not_defined | 5,456,114 | 5,467,866 | - | - |
RefSeq Transcripts (Human)
| Accession | Type | Status | MANE Select |
|---|
| NM_014143 | mRNA | REVIEWED | ✓ Yes |
| NM_001267706 | mRNA | REVIEWED | No |
| NM_001314029 | mRNA | REVIEWED | No |
| NR_052005 | ncRNA | REVIEWED | No |
| XM_047423262 | mRNA | PREDICTED | No |
| XM_054362810 | mRNA | PREDICTED | No |
CCDS IDs
Total: 2
Exons (Canonical Transcript ENST00000381577)
Total: 7 exons
| Exon ID | Start | End | Strand |
|---|
| ENSE00001892659 | 5,450,542 | 5,450,596 | + |
| ENSE00000813155 | 5,456,100 | 5,456,165 | + |
| ENSE00003541119 | 5,457,079 | 5,457,420 | + |
| ENSE00000813157 | 5,462,834 | 5,463,121 | + |
| ENSE00000813158 | 5,465,499 | 5,465,606 | + |
| ENSE00003507383 | 5,466,770 | 5,466,829 | + |
| ENSE00001889081 | 5,467,840 | 5,470,554 | + |
Section 3: Protein Identifiers
UniProt Accessions
Total: 1 reviewed entry
| Accession | Name | Status | Mass | Length |
|---|
| Q9NZQ7 | Programmed cell death 1 ligand 1 | Reviewed (Swiss-Prot) | 33,275 Da | 290 aa |
Alternative Names: B7 homolog 1
RefSeq Protein Accessions
| Accession | Status | MANE Select |
|---|
| NP_054862 | REVIEWED | ✓ Yes |
| NP_001254635 | REVIEWED | No |
| NP_001300958 | REVIEWED | No |
| XP_047279218 | PREDICTED | No |
| XP_054218785 | PREDICTED | No |
Protein Domains and Families
Total: 7 InterPro entries
| InterPro ID | Name | Type |
|---|
| IPR003599 | Ig_sub | Domain |
| IPR007110 | Ig-like_dom | Domain |
| IPR013106 | Ig_V-set | Domain |
| IPR013162 | CD80_C2-set | Domain |
| IPR013783 | Ig-like_fold | Homologous_superfamily |
| IPR036179 | Ig-like_dom_sf | Homologous_superfamily |
| IPR051713 | T-cell_Activation_Regulation | Family |
Section 4: Structure Identifiers
Experimental Structures (PDB)
Total: 74 structures
| PDB ID | Title | Method | Resolution |
|---|
| 5O45 | PD-L1 in complex with inhibitor | X-RAY | 0.99 Å |
| 8ALX | PD-L1 in complex with inhibitor | X-RAY | 1.10 Å |
| 6NP9 | PD-L1 IgV domain V76T with fragment | X-RAY | 1.27 Å |
| 9I0U | PD-L1 with clinically evaluated inhibitor | X-RAY | 1.46 Å |
| 6YCR | PD-L1 in complex with inhibitor | X-RAY | 1.54 Å |
| 7CZD | PD-L1 complexed with VHH | X-RAY | 1.64 Å |
| 5JDS | PD-L1 complexed with nanobody | X-RAY | 1.70 Å |
| 5N2F | PD-L1/small-molecule inhibitor complex | X-RAY | 1.70 Å |
| 7ZNL | PD-L1 de novo designed binder | X-RAY | 1.77 Å |
| 5C3T | PD-1 binding domain from human PD-L1 | X-RAY | 1.80 Å |
| 7OUN | PD-L1 with macrocyclic inhibitor | X-RAY | 1.90 Å |
| 6NNV | PD-L1 IgV with macro-cyclic peptide | X-RAY | 1.92 Å |
| 4Z18 | Crystal structure of human PD-L1 | X-RAY | 1.95 Å |
| 6PV9 | PD-L1 bound to macrocyclic peptide | X-RAY | 2.00 Å |
| 7SJQ | Bispecific T-cell engager | X-RAY | 2.00 Å |
| 5NIU | PD-L1 with low molecular mass inhibitor | X-RAY | 2.01 Å |
| 9IJT | PD-L1 bound to small molecule inhibitor | X-RAY | 2.05 Å |
NMR Structures:
| PDB ID | Title | Method |
|---|
| 6L8R | Membrane-bound PD-L1-CD | SOLUTION NMR |
| 7DCV | Transmembrane domain of human PD-L1 | SOLUTION NMR |
AlphaFold Predicted Structure
| Attribute | Value |
|---|
| AlphaFold ID | Q9NZQ7 |
| Global pLDDT | 88.13 |
| Sequence Length | 2,339 |
| Fraction pLDDT Very High | 70% |
Section 5: Cross-Species Orthologs
| Organism | Gene ID | Symbol | Biotype |
|---|
| Mouse (Mus musculus) | ENSMUSG00000016496 | Cd274 | protein_coding |
| Rat (Rattus norvegicus) | ENSRNOG00000016112 | Cd274 | protein_coding |
Human Paralogs
Total: 12 paralogs
| Gene ID | Symbol | Description |
|---|
| ENSG00000197646 | PDCD1LG2 | PD-L2 (closest paralog) |
| ENSG00000121594 | CD80 | B7-1 |
| ENSG00000114013 | CD86 | B7-2 |
| ENSG00000128250 | RFPL1 | Ret finger protein like 1 |
| ENSG00000128253 | RFPL2 | Ret finger protein like 2 |
| ENSG00000128276 | RFPL3 | Ret finger protein like 3 |
| ENSG00000176422 | SPRYD4 | SPRY domain containing 4 |
| ENSG00000176641 | RNF152 | Ring finger protein 152 |
| ENSG00000181481 | RNF135 | Ring finger protein 135 |
| ENSG00000223638 | RFPL4A | Ret finger protein like 4A |
| ENSG00000229292 | RFPL4AL1 | RFPL4A like 1 |
| ENSG00000251258 | RFPL4B | Ret finger protein like 4B |
Section 6: Clinical Variants & AI Predictions
ClinVar Variants
Total: 29 variants
By Classification:
| Classification | Count |
|---|
| Pathogenic | 4 |
| Likely Benign | 2 |
| Benign | 4 |
| Uncertain Significance | 15 |
| Not Provided | 4 |
Pathogenic/Likely Pathogenic Variants
| ClinVar ID | Variant | Type | Classification |
|---|
| 3906943 | CD274, IVS4DS, G-A, +1 | SNV | Pathogenic |
| 1703576 | 9p24.3-q13 (chr9:203861-68342786) | CNV gain | Pathogenic |
| 1706515 | 9p24.3-23 (chr9:203861-10283912)x1 | CNV loss | Pathogenic |
| 442671 | 9p24.3-23 (chr9:203861-13486759)x1 | CNV loss | Pathogenic |
| 563686 | 9p24.3-q21.11 (chr9:203861-70985795)x4 | CNV gain | Pathogenic |
Select Missense Variants of Uncertain Significance
| ClinVar ID | HGVS | Protein Change |
|---|
| 2208831 | c.548A>C | p.Asn183Thr |
| 2307554 | c.829A>G | p.Thr277Ala |
| 3140479 | c.649G>A | p.Glu217Lys |
| 3264788 | c.436C>A | p.Pro146Thr |
| 3998155 | c.832A>C | p.Asn278His |
| 3998156 | c.343A>G | p.Met115Val |
| 4222761 | c.615G>C | p.Glu205Asp |
| 4650550 | c.545C>T | p.Thr182Ile |
| 4650551 | c.526A>T | p.Ser176Cys |
SpliceAI Predictions
Total: 1,102 predicted splice-altering variants
TOP 20 High-Impact Splice Variants (Delta Score ≥0.9)
| Variant | Effect | Score |
|---|
| 9:5450594:CAG:C | donor_loss | 1.00 |
| 9:5450595:AGG:A | donor_loss | 1.00 |
| 9:5450596:GG:G | donor_loss | 0.99 |
| 9:5450597:GTA:G | donor_loss | 0.99 |
| 9:5450598:T:G | donor_loss | 0.99 |
| 9:5450593:GCAG:G | donor_gain | 0.97 |
| 9:5452003:G:GT | donor_gain | 0.97 |
| 9:5450597:G:GG | donor_gain | 0.92 |
AlphaMissense Predictions
Total: 1,923 predicted missense variant effects
Most variants in CD274 are predicted as likely_benign with a few classified as ambiguous:
| Variant | Protein | AM Score | Class |
|---|
| 9:5456132:T:C | F7L | 0.412 | ambiguous |
| 9:5456134:T:A | F7L | 0.412 | ambiguous |
| 9:5456134:T:G | F7L | 0.412 | ambiguous |
| 9:5456138:T:C | F9L | 0.371 | ambiguous |
| 9:5456140:C:A | F9L | 0.371 | ambiguous |
| 9:5456140:C:G | F9L | 0.371 | ambiguous |
Section 7: Biological Pathways & Gene Ontology
Reactome Pathways
Total: 8 pathways
| Pathway ID | Name |
|---|
| R-HSA-389948 | Co-inhibition by PD-1 |
| R-HSA-9701898 | STAT3 nuclear events downstream of ALK signaling |
| R-HSA-9909620 | Regulation of PD-L1(CD274) translation |
| R-HSA-9909649 | Regulation of PD-L1(CD274) transcription |
| R-HSA-9929356 | GSK3B-mediated proteasomal degradation of PD-L1 |
| R-HSA-9929491 | SPOP-mediated proteasomal degradation of PD-L1 |
| R-HSA-9931269 | AMPK-induced ERAD and lysosome mediated degradation of PD-L1 |
| R-HSA-9931295 | PD-L1 glycosylation and translocation to plasma membrane |
Gene Ontology Annotations
Total: 36 GO terms
Biological Process (22 terms)
| GO ID | Term |
|---|
| GO:0002250 | adaptive immune response |
| GO:0002376 | immune system process |
| GO:0002841 | negative regulation of T cell mediated immune response to tumor cell |
| GO:0006955 | immune response |
| GO:0007165 | signal transduction |
| GO:0007166 | cell surface receptor signaling pathway |
| GO:0031295 | T cell costimulation |
| GO:0032689 | negative regulation of type II interferon production |
| GO:0032693 | negative regulation of interleukin-10 production |
| GO:0032733 | positive regulation of interleukin-10 production |
| GO:0034097 | response to cytokine |
| GO:0035666 | TRIF-dependent toll-like receptor signaling pathway |
| GO:0042102 | positive regulation of T cell proliferation |
| GO:0042130 | negative regulation of T cell proliferation |
| GO:0045893 | positive regulation of DNA-templated transcription |
| GO:0046007 | negative regulation of activated T cell proliferation |
| GO:0050868 | negative regulation of T cell activation |
| GO:0071222 | cellular response to lipopolysaccharide |
| GO:1903556 | negative regulation of TNF superfamily cytokine production |
| GO:1905404 | positive regulation of activated CD8+ T cell apoptotic process |
| GO:2000562 | negative regulation of CD4+ T cell proliferation |
| GO:2001186 | negative regulation of CD8+ T cell activation |
Molecular Function (3 terms)
| GO ID | Term |
|---|
| GO:0003713 | transcription coactivator activity |
| GO:0005515 | protein binding |
| GO:0048018 | receptor ligand activity |
Cellular Component (11 terms)
| GO ID | Term |
|---|
| GO:0005576 | extracellular region |
| GO:0005654 | nucleoplasm |
| GO:0005768 | endosome |
| GO:0005886 | plasma membrane |
| GO:0009897 | external side of plasma membrane |
| GO:0012505 | endomembrane system |
| GO:0015629 | actin cytoskeleton |
| GO:0016020 | membrane |
| GO:0031901 | early endosome membrane |
| GO:0055038 | recycling endosome membrane |
| GO:0070062 | extracellular exosome |
Section 8: Protein Interactions & Molecular Networks
IntAct Protein-Protein Interactions
Total: 61 experimentally validated interactions
Primary Binding Partners (High Confidence)
| Partner Gene | Partner Protein | Interaction Type | Confidence |
|---|
| PDCD1 | PD-1 (Q15116) | Direct interaction | 0.890 |
| CD80 | B7-1 (P33681) | Direct interaction | 0.950 |
| PDCD1LG2 | PD-L2 (Q9BQ51) | Physical association | 0.740 |
| CMTM6 | CMTM6 | Physical association | 0.690 |
| CMTM4 | CMTM4 | Physical association | 0.500 |
| NCR3 | NKp30 | Physical association | 0.400 |
| CD274 | Self-interaction | Direct interaction | 0.440 |
STRING Interaction Network
Total: 4,400+ interactions
TOP 30 Highest-Confidence Interactors
| Partner UniProt | Partner Gene | Score |
|---|
| Q15116 | PDCD1 (PD-1) | 999 |
| P16410 | CTLA4 | 999 |
| P10747 | CD80 | 997 |
| Q8TDQ0 | PDCD1LG2 | 998 |
| Q9Y6W8 | ICOS | 995 |
| P33681 | CD80 | 989 |
| P18627 | LAG3 | 975 |
| Q9BQ51 | PDCD1LG2 | 970 |
| P42081 | CD86 | 969 |
| P40763 | STAT3 | 968 |
| P01732 | CD8A | 937 |
| Q9BZS1 | FOXP3 | 912 |
| P00533 | EGFR | 870 |
| P08637 | FCGR3A | 866 |
| Q06124 | PTPN11 | 863 |
| P01585 | IFNA2 | 853 |
| P43489 | TNFRSF4 | 850 |
| P25942 | CD40 | 838 |
| P04626 | ERBB2 | 798 |
| P15056 | BRAF | 792 |
| P01375 | TNF | 780 |
| P01730 | CD4 | 883 |
| P01579 | IFNG | 882 |
| P14902 | IDO1 | 880 |
| P22301 | IL10 | 876 |
CellPhoneDB Ligand-Receptor Pairs
| Interaction ID | Partner A | Partner B | Classification |
|---|
| CPI-SS09D4B2070 | CD274 | PDCD1 (PD-1) | Ligand-Receptor |
| CPI-SS0D7DB794A | CD274 | CD80 (B7-1) | Ligand-Receptor |
Protein Similarity
ESM2 Structural Embedding Similarity
Total: 38 similar proteins
| UniProt | Top Similarity | Avg Similarity |
|---|
| O35112 (Mouse PD-L1) | 0.9999 | 0.9838 |
| O46634 | 0.9994 | 0.9832 |
| P04218 (CD80) | 0.9995 | 0.9826 |
| Q13740 (CD166/ALCAM) | 0.9997 | 0.9837 |
| Q9BH13 (VSIG4) | 0.9996 | 0.9831 |
| P42081 (CD86) | 0.9955 | 0.9828 |
| O75144 (ICOSLG) | 0.9778 | 0.9592 |
DIAMOND Sequence Homology
Total: 6 homologous proteins
| UniProt | Identity | Bitscore |
|---|
| Q2VWP7 (Chimpanzee) | 89.9% | 1999 |
| Q589G5 (Macaque) | 85.5% | 1922 |
| Q9BQ51 (PD-L2) | 69.6% | 336 |
| Q9EP73 (Mouse PD-L2) | 69.4% | 397 |
| Q9WUL5 (Mouse PD-L1) | 69.9% | 337 |
Section 9: Transcription Factor Regulatory Data
Upstream Regulators (CollecTRI)
Total: 7 transcription factors regulate CD274
| TF Gene | Regulation | Confidence |
|---|
| STAT3 | Activation | High |
| HIF1A | Activation | - |
| IRF1 | Activation | Low |
| KMT2C | Activation | - |
| NFKB | Unknown | High |
| STAT1 | Unknown | - |
| FOXA1 | Repression | High |
SIGNOR Signaling Network
Total: 26 regulatory relationships
Proteins that REGULATE CD274
| Regulator | Effect | Mechanism |
|---|
| STAT3 | up-regulates | transcriptional regulation |
| HIF1A | up-regulates | transcriptional regulation |
| KMT2C | up-regulates | transcriptional regulation |
| FOXP3 | up-regulates | transcriptional regulation |
| CMTM6 | stabilizes | stabilization |
| CMTM4 | stabilizes | stabilization |
| STT3A | stabilizes | glycosylation |
| STT3B | stabilizes | glycosylation |
| B3GNT3 | activates | glycosylation |
| NEK2 | stabilizes | phosphorylation |
| COPS5 | stabilizes | deubiquitination |
| SIGMAR1 | stabilizes | stabilization |
| FKBP5 | up-regulates | catalytic activity |
| GSK3B | destabilizes | phosphorylation |
| GSK3A | destabilizes | phosphorylation |
| SPOP | down-regulates | ubiquitination |
| STUB1 | destabilizes | destabilization |
| ARIH1 | destabilizes | ubiquitination |
| ITCH | destabilizes | ubiquitination |
| SCF-betaTRCP | destabilizes | polyubiquitination |
CD274 REGULATES (Downstream Target)
| Target | Effect | Mechanism | Score |
|---|
| PDCD1 (PD-1) | up-regulates | binding | 0.94 |
Note: CD274 is NOT a transcription factor. It does not have DNA binding motifs or regulate gene transcription directly.
Section 10: Drug & Pharmacology Data
ChEMBL Targets
Total: 4 target entries
| ChEMBL ID | Target Name | Type |
|---|
| CHEMBL3580522 | Programmed cell death 1 ligand 1 | SINGLE PROTEIN |
| CHEMBL4523993 | PD-1/PD-L1 complex | PROTEIN COMPLEX |
| CHEMBL5739543 | Cereblon/PD-L1 | PROTEIN-PROTEIN INTERACTION |
| CHEMBL6066575 | PD-L1/L2 | PROTEIN FAMILY |
FDA-Approved Anti-PD-L1 Antibodies (Phase 4)
| ChEMBL ID | Name | Trade Name | Type | ATC |
|---|
| CHEMBL3707227 | ATEZOLIZUMAB | Tecentriq | Antibody | L01FF05 |
| CHEMBL3301587 | DURVALUMAB | Imfinzi | Antibody | L01FF03 |
| CHEMBL3833373 | AVELUMAB | Bavencio | Antibody | L01FF04 |
Clinical Trials (Atezolizumab Example)
Total: 685+ clinical trials
Phase 4 Trials
| NCT ID | Title | Status |
|---|
| NCT03285763 | Long-term Safety in NSCLC | COMPLETED |
| NCT05185505 | Pre-Liver Transplant for HCC | RECRUITING |
| NCT05689671 | TTF-1 Negative Lung Adenocarcinoma | RECRUITING |
Select Phase 3 Trials
| NCT ID | Title | Status |
|---|
| NCT02008227 | IMpower: Atezolizumab vs Docetaxel in NSCLC | COMPLETED |
| NCT02302807 | IMvigor211: Urothelial Carcinoma | COMPLETED |
| NCT02425891 | IMpassion130: Triple-Negative Breast Cancer | COMPLETED |
| NCT02763579 | IMpower133: Extensive-Stage SCLC | COMPLETED |
| NCT03434379 | IMbrave150: HCC with Bevacizumab | COMPLETED |
PharmGKB Pharmacogenomics
Gene Status: VIP (Very Important Pharmacogene)
| PharmGKB ID | Symbol | Chromosome | CPIC Guideline |
|---|
| PA134915280 | CD274 | chr9 | No |
Associated Drugs
| PharmGKB ID | Drug | Clinical Annotations | Variant Annotations |
|---|
| PA166124615 | pembrolizumab | 0 | 12 |
| PA166129522 | nivolumab | 0 | 11 |
| PA166129523 | atezolizumab | 0 | 7 |
| PA166169875 | avelumab | 0 | 5 |
| PA166169883 | durvalumab | 0 | 6 |
| PA166182718 | ipilimumab | 0 | 9 |
| PA449014 | cisplatin | 123 | 541 |
| PA448803 | carboplatin | 65 | 134 |
| PA10810 | pemetrexed | 12 | 29 |
Section 11: Expression Profiles
Bgee Expression Data
Expression Breadth: UBIQUITOUS
| Metric | Value |
|---|
| Total Present Calls | 208 |
| Total Absent Calls | 37 |
| Total Conditions | 245 |
| Max Expression Score | 88.56 |
| Average Expression Score | 64.82 |
| Gold Quality Count | 219 |
TOP 30 Expressing Tissues/Cell Types
| Rank | Tissue/Cell Type | Score | Quality |
|---|
| 1 | Cartilage tissue | 88.56 | Gold |
| 2 | Placenta | 86.83 | Gold |
| 3 | Lower lobe of lung | 86.80 | Gold |
| 4 | Epithelial cell of pancreas | 86.75 | Gold |
| 5 | Upper lobe of left lung | 85.84 | Gold |
| 6 | Upper lobe of lung | 85.72 | Gold |
| 7 | Right lung | 84.89 | Gold |
| 8 | Left ventricle myocardium | 84.81 | Gold |
| 9 | Vermiform appendix | 83.83 | Gold |
| 10 | Pancreatic ductal cell | 83.03 | Gold |
| 11 | Male germ line stem cell in testis | 82.44 | Gold |
| 12 | Lung | 82.26 | Gold |
| 13 | Heart right ventricle | 82.22 | Gold |
| 14 | Myocardium | 81.56 | Gold |
| 15 | Heart left ventricle | 81.30 | Gold |
| 16 | Spleen | 81.26 | Gold |
| 17 | Cardiac ventricle | 81.01 | Gold |
| 18 | Ileal mucosa | 79.96 | Gold |
| 19 | Heart | 77.79 | Gold |
| 20 | Lymph node | 77.40 | Gold |
| 21 | Tibialis anterior | 77.12 | Silver |
| 22 | Apex of heart | 76.82 | Gold |
| 23 | Blood | 76.43 | Gold |
| 24 | Right atrium auricular region | 76.40 | Gold |
| 25 | Thymus | 76.35 | Gold |
| 26 | Cardiac atrium | 76.04 | Gold |
| 27 | Stromal cell of endometrium | 75.58 | Gold |
| 28 | Caecum | 75.53 | Gold |
| 29 | Deltoid | 75.35 | Silver |
| 30 | Gall bladder | 75.04 | Gold |
Single-Cell Expression Data
Total: 3 datasets
| Experiment ID | Description | Species | Cells |
|---|
| E-CURD-10 | Metastatic renal cell carcinoma PDX | Human | 118 |
| E-MTAB-7037 | Dermal fibroblasts stimulation with dsRNA | Human | 590 |
| E-MTAB-8498 | Dendritic cell subsets in acute skin inflammation | Human | 729 |
Section 12: Disease Associations
GenCC Gene-Disease Validity
| Disease | Classification | Inheritance | Submitter |
|---|
| Neonatal diabetes mellitus | Limited | Autosomal recessive | Ambry Genetics |
GWAS Associations
Total: 1 association
| Study ID | Trait | P-value |
|---|
| GCST006585_2315 | Blood protein levels | 2.0 × 10⁻²⁹ |
MSigDB Gene Set Membership
Total: 426+ gene sets
Key Cancer/Immune Gene Sets
| Gene Set | Collection | Description |
|---|
| REACTOME_CO_INHIBITION_BY_PD_1 | C2:CP | Core PD-1 co-inhibitory pathway |
| REACTOME_ADAPTIVE_IMMUNE_SYSTEM | C2:CP | Adaptive immunity |
| KEGG_CELL_ADHESION_MOLECULES_CAMS | C2:CP | Cell adhesion |
| GOBP_NEGATIVE_REGULATION_OF_T_CELL_ACTIVATION | C5:GO | T cell inhibition |
| GOBP_NEGATIVE_REGULATION_OF_T_CELL_PROLIFERATION | C5:GO | T cell growth suppression |
PD-L1 Expression in Cancer (Clinical Relevance)
CD274 (PD-L1) expression is a prognostic and predictive biomarker in multiple malignancies:
- Non-Small Cell Lung Cancer (NSCLC): PD-L1 TPS ≥50% or ≥1% determines pembrolizumab eligibility
- Urothelial Carcinoma: CPS scoring for checkpoint inhibitor selection
- Triple-Negative Breast Cancer: PD-L1 IC ≥1% for atezolizumab combination
- Hepatocellular Carcinoma: Atezolizumab + bevacizumab first-line therapy
- Renal Cell Carcinoma: Multiple checkpoint inhibitor combinations approved
- Melanoma: PD-L1 status informs immunotherapy decisions
SUMMARY STATISTICS
| Category | Count |
|---|
| Gene Identifiers | 4 (HGNC, Ensembl, Entrez, OMIM) |
| Transcripts (Ensembl) | 5 |
| RefSeq mRNA | 4 (human) |
| CCDS | 2 |
| Exons (canonical) | 7 |
| UniProt Entries | 1 (reviewed) |
| Protein Length | 290 aa |
| InterPro Domains | 7 |
| PDB Structures | 74 |
| Orthologs | 2 (mouse, rat) |
| Paralogs | 12 |
| ClinVar Variants | 29 |
| SpliceAI Predictions | 1,102 |
| AlphaMissense Predictions | 1,923 |
| Reactome Pathways | 8 |
| GO Terms | 36 |
| STRING Interactions | 4,400+ |
| IntAct Interactions | 61 |
| Upstream TF Regulators | 7 |
| Approved Targeting Drugs | 3 (atezolizumab, durvalumab, avelumab) |
| Clinical Trials (atezolizumab) | 685+ |
| Expressing Tissues | 208 |
| MSigDB Gene Sets | 426+ |
╔══════════════════════════════════════════════════════════════════════════════╗
║ Reference compiled from: BioBTree, HGNC, Ensembl, NCBI, UniProt, PDB, ║
║ ClinVar, AlphaMissense, SpliceAI, Reactome, GO, STRING, IntAct, ChEMBL, ║
║ PharmGKB, Bgee, Single Cell Expression Atlas, GenCC, GWAS Catalog, MSigDB ║
╚══════════════════════════════════════════════════════════════════════════════╝
The comprehensive cross-database identifier and functional mapping reference for CD274 (PD-L1) is now complete. This document covers all 12 requested sections with:
Key Highlights:
- 74 experimental PDB structures (best resolution: 0.99 Å)
- 3 FDA-approved targeting antibodies: Atezolizumab, Durvalumab, Avelumab
- 685+ clinical trials for atezolizumab alone
- Primary binding partners: PD-1 (PDCD1) and CD80 (B7-1) with confidence scores >0.89
- 7 transcription factors regulate CD274 expression (STAT3, HIF1A, IRF1, FOXP3, NFKB, STAT1, FOXA1)
- Ubiquitous expression with highest levels in placenta, lung, and immune tissues
- 1,923 AlphaMissense predictions and 1,102 SpliceAI predictions for variant interpretation
- Designated as a VIP (Very Important Pharmacogene) in PharmGKB
This reference serves as a definitive lookup resource for CD274/PD-L1 research across genomics, structural biology, pharmacology, and clinical applications.